pneumococcal saccharide conjugated vaccine

Pneumococcal saccharide conjugated vaccine refers to a class of conjugate vaccines (PCVs) designed to prevent invasive disease and pneumonia caused by *Streptococcus pneumoniae*. These vaccines consist of purified capsular polysaccharides from various pneumococcal serotypes, each covalently linked to a carrier protein, such as CRM197 (a non-toxic recombinant variant of diphtheria toxin). This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, enabling the induction of immunological memory and a more robust immune response, particularly in infants and older adults. While the term is a generic descriptor for the PCV platform (including products like Prevnar 13 and Prevnar 20), the specific context of trial jRCT2080223966 identifies the 15-valent candidate **V114** (Vaxneuvance) developed by Merck (MSD). V114 includes the 13 serotypes found in PCV13 plus serotypes 22F and 33F, which are significant contributors to invasive pneumococcal disease globally. The vaccine is typically adsorbed onto an aluminum phosphate adjuvant and administered via intramuscular injection.

Brand names

Vaxneuvance

Other names

15-valent pneumococcal conjugate vaccinePCV15PCV-15PCV 15pneumococcal 15-valent conjugate vaccinepneumococcal15-valent conjugate vaccinepneumococcal-15-valent conjugate vaccineAdsorbed 15-valent pneumococcal conjugate vaccineAdsorbed15-valent pneumococcal conjugate vaccineAdsorbed-15-valent pneumococcal conjugate vaccine